Compare Stocks → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GMDANASDAQ:GNFTNASDAQ:INMBNASDAQ:LOGCNASDAQ:TARA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMDAGamida Cell$0.02$0.23$0.03▼$2.51$2.39M0.939.20 million shs3.57 million shsGNFTGenfit$3.45$3.59$2.89▼$4.75$171.66M1.084,408 shs3,539 shsINMBINmune Bio$10.26-3.4%$11.46$6.50▼$14.74$186.73M1.9995,722 shs16,892 shsLOGCLogicBio Therapeutics$2.07$2.06$0.26▼$3.77$68.23M4.61652,526 shsN/ATARAProtara Therapeutics$2.96+5.0%$3.75$1.04▼$5.24$33.83M1.71213,887 shs82,147 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMDAGamida Cell-8.62%-11.18%-95.53%-96.30%-99.04%GNFTGenfit+0.44%-0.43%-5.36%-11.21%-7.89%INMBINmune Bio+4.73%+25.98%-9.31%-10.08%+50.64%LOGCLogicBio Therapeutics0.00%0.00%0.00%0.00%0.00%TARAProtara Therapeutics-6.00%+3.30%-29.32%+20.00%-9.62%Wall Street Legend Issues New NVDA Warning (Ad)Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMDAGamida Cell0.5988 of 5 stars3.42.00.00.00.00.80.0GNFTGenfit0.81 of 5 stars3.53.00.00.00.60.00.0INMBINmune Bio0.7786 of 5 stars3.50.00.00.01.71.70.0LOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATARAProtara Therapeutics2.0361 of 5 stars3.53.00.00.02.40.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMDAGamida Cell2.75Moderate Buy$4.7530,545.16% UpsideGNFTGenfit3.00Buy$11.00219.30% UpsideINMBINmune Bio3.00Buy$16.0055.95% UpsideLOGCLogicBio TherapeuticsN/AN/AN/AN/ATARAProtara Therapeutics3.00Buy$26.50795.27% UpsideCurrent Analyst RatingsLatest LOGC, GNFT, GMDA, TARA, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024TARAProtara TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.004/8/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.004/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/14/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.001/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMDAGamida Cell$1.78M1.34N/AN/A($0.02) per share-0.78GNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33INMBINmune Bio$160K1,167.08N/AN/A$2.07 per share4.96LOGCLogicBio Therapeutics$5.41M12.61N/AN/A$0.48 per share4.31TARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)INMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)LOGCLogicBio Therapeutics-$40.03M-$0.81N/AN/AN/A-246.71%-115.29%-53.01%N/ATARAProtara Therapeutics-$40.42M-$3.57N/AN/AN/AN/A-49.71%-43.82%5/2/2024 (Estimated)Latest LOGC, GNFT, GMDA, TARA, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/13/2024Q4 2023TARAProtara Therapeutics-$1.03-$0.90+$0.13-$0.90N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMDAGamida CellN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMDAGamida Cell213.142.162.09GNFTGenfit0.922.942.94INMBINmune BioN/A2.162.16LOGCLogicBio Therapeutics0.171.992.26TARAProtara TherapeuticsN/A11.1711.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMDAGamida Cell50.34%GNFTGenfit2.24%INMBINmune Bio12.72%LOGCLogicBio Therapeutics39.11%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipGMDAGamida Cell3.40%GNFTGenfit4.20%INMBINmune Bio36.10%LOGCLogicBio Therapeutics8.10%TARAProtara Therapeutics18.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableINMBINmune Bio1118.20 million11.63 millionOptionableLOGCLogicBio Therapeutics6232.96 million30.29 millionNot OptionableTARAProtara Therapeutics2611.43 million9.33 millionOptionableLOGC, GNFT, GMDA, TARA, and INMB HeadlinesSourceHeadlineProtara Therapeutics (NASDAQ:TARA) Given New $30.00 Price Target at Oppenheimeramericanbankingnews.com - April 23 at 3:26 AMProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54msn.com - April 17 at 12:11 PMProtara Therapeutics, Inc. (TARA)finance.yahoo.com - April 15 at 6:45 PMHere's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Nowzacks.com - April 12 at 10:56 AMBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatmentmarkets.businessinsider.com - April 9 at 2:25 AMProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equitymsn.com - April 5 at 3:10 PMProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloridemarkets.businessinsider.com - April 5 at 10:10 AMProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Upmarkets.businessinsider.com - April 5 at 10:10 AMProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financingglobenewswire.com - April 5 at 8:04 AMProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutritionglobenewswire.com - April 5 at 8:02 AMProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCglobenewswire.com - April 5 at 8:00 AM3 Stocks That Could Help You Retire on a Private Islandinvestorplace.com - March 23 at 6:00 AMBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunitymarkets.businessinsider.com - March 13 at 6:27 PMProtara Therapeutics: Q4 Earnings Snapshotchron.com - March 13 at 1:26 PMProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 13 at 8:00 AMTARA Aug 2024 7.500 callfinance.yahoo.com - March 3 at 11:42 PMTARA May 2024 2.500 putfinance.yahoo.com - March 3 at 11:42 PMNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024theglobeandmail.com - February 28 at 7:58 PMProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 8:00 AMNorthSea Therapeutics commences Phase IIa trial for IFALD therapymsn.com - February 22 at 7:53 PMWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Ratefinance.yahoo.com - February 17 at 8:43 AMCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionalityseekingalpha.com - January 25 at 3:04 PMOppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)markets.businessinsider.com - December 2 at 7:37 PMProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncologyfinance.yahoo.com - November 30 at 12:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.LogicBio TherapeuticsNASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Protara TherapeuticsNASDAQ:TARAProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.